Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.56 |
| ▸ | LOX | P28300 | 1/20 | 0.54 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | TYMS | P04818 | 1/20 | 0.34 |
| ▸ | PDPK1 | O15530 | 2/20 | 0.33 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.33 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.33 |
| ▸ | VNN1 | O95497 | 1/20 | 0.32 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.32 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.32 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.31 |
| ▸ | MMP13 | P45452 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29988304 | 1.00 | LOXL2 (0.56) | LOXL2LOXKCNQ2S1PR1NOTUM | |
| SCHEMBL19751483 | 0.84 | LOXL2 (0.39) | LOXL2LOXKCNQ2S1PR1 | |
| SCHEMBL15409505 | 0.78 | KDM4E (0.41) | S1PR1 | |
| SCHEMBL21594398 | 0.75 | TRPV4 (0.43) | S1PR1PDPK1 | |
| SCHEMBL28799681 | 0.75 | RECQL (0.52) | LOXL2LOXIDO1 | |
| SCHEMBL15426707 | 0.73 | LOXL2 (0.38) | LOXL2LOXS1PR1 | |
| SCHEMBL18012380 | 0.72 | HDAC3 (0.33) | — | |
| SCHEMBL8224465 | 0.72 | LOXL2 (0.67) | LOXL2LOXKCNQ2NOTUMIDO1 | |
| SCHEMBL16388355 | 0.72 | LOXL2 (0.67) | LOXL2LOXKCNQ2NOTUMIDO1 | |
| SCHEMBL16047057 | 0.72 | LOXL2 (0.67) | LOXL2LOXKCNQ2NOTUMIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2025064718-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| US-12133841-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOMED HOLDINGS LTD. (KY) | 2024-11-05 | — | — | US | disclosed |
| CN-112638917-B | Heterocyclic compounds as kinase inhibitors, compositions comprising the same, and methods of use thereof | 捷思英达控股有限公司 | 2023-09-08 | — | — | CN | disclosed |
| WO-2023036140-A1 | 3CLPRO PROTEASE INHIBITOR | 上海齐鲁制药研究中心有限公司 | 2023-03-16 | — | — | WO | disclosed |
| CN-111032656-B | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2022-12-02 | — | — | CN | disclosed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | JS INNOPHARM (SHANGHAI) LTD. (CN) | 2022-02-08 | — | — | US | disclosed |
| US-20210188868-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-20210188868-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOMED HOLDINGS LTD. (KY) | 2021-06-24 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | JS INNOPHARM (SHANGHAI) LTD (CN) | 2020-07-30 | — | — | US | disclosed |
| CN-111032656-A | Heterocyclic compound kinase inhibitor and pharmaceutical composition and application thereof | 捷思英达医药技术（上海）有限公司 | 2020-04-17 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200239438-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K20, MAP3K19, MAP3K1 | LOXL2 2287/4885LOX 1661/4885KCNQ2 1808/4885 |
| US-20250129021-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | MYC, KRAS, NRAS | LOXL2 2287/4885LOX 1958/4885KCNQ2 3220/4885 |
| US-20210188868-A1 | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS, COMPOSITIONS COMPRISING THE HETEROCYCLIC COMPOUND, AND METHODS OF USE THEREOF | MAP3K11, MAP3K13, MAP3K1 | LOXL2 2588/4885LOX 1705/4885KCNQ2 2236/4885 |
| US-11242334-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K20, MAP3K19, MAP3K1 | LOXL2 2287/4885LOX 1661/4885KCNQ2 1808/4885 |
| US-12133841-B2 | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | MAP3K11, MAP3K13, MAP3K1 | LOXL2 2588/4885LOX 1705/4885KCNQ2 2236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.